Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2007

Open Access 01-12-2007 | Research article

T-cell and serological responses to Erp, an exported Mycobacterium tuberculosisprotein, in tuberculosis patients and healthy individuals

Authors: Valérie Martinez, Guislaine Carcelain, Edgar Badell, Marc Jouan, Isabelle Mauger, Pierre Sellier, Chantal Truffot, François Bricaire, Sandra M Arend, Tom Ottenhoff, Brigitte Autran, Brigitte Gicquel

Published in: BMC Infectious Diseases | Issue 1/2007

Login to get access

Abstract

Background

The identification of antigens able to differentiate tuberculosis (TB) disease from TB infection would be valuable. Cellular and humoral immune responses to Erp (Exported repetitive protein) – a recently identified M. tuberculosis protein – have not yet been investigated in humans and may contribute to this aim.

Methods

We analyzed the cellular and humoral immune responses to Erp, ESAT-6, Ag85B and PPD in TB patients, in BCG+ individuals without infection, BCG+ individuals with latent TB infection (LTBI) and BCG- controls. We used lymphoproliferation, ELISpot IFN-γ, cytokine production assays and detection of specific human antibodies against recombinant M. tuberculosis proteins.

Results

We included 22 TB patients, 9 BCG+ individuals without TB infection, 7 LTBI and 7 BCG- controls. Erp-specific T cell counts were higher in LTBI than in the other groups. Erp-specific T cell counts were higher in LTBI subjects than TB patients (median positive frequency of 211 SFC/106 PBMC (range 118–2000) for LTBI subjects compared to 80 SFC/106 PBMC (range 50–191), p = 0.019); responses to PPD and ESAT-6 antigens did not differ between these groups. IFN-γ secretion after Erp stimulation differed between TB patients and LTBI subjects (p = 0.02). Moreover, LTBI subjects but not TB patients or healthy subjects produced IgG3 against Erp.

Conclusion

The frequencies of IFN-γ-producing specific T cells, the IFN-γ secretion and the production of IgG3 after Erp stimulation are higher in LTBI subjects than in TB patients, whereas PPD and ESAT-6 are not.
Appendix
Available only for authorised users
Literature
1.
Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. Jama. 1999, 282 (7): 677-686. 10.1001/jama.282.7.677.CrossRefPubMed
2.
Chan J, Flynn J: The immunological aspects of latency in tuberculosis. Clin Immunol. 2004, 110 (1): 2-12. 10.1016/S1521-6616(03)00210-9.CrossRefPubMed
3.
Kaufmann SH: How can immunology contribute to the control of tuberculosis?. Nat Rev Immunol. 2001, 1 (1): 20-30. 10.1038/35095558.CrossRefPubMed
4.
Flynn JL, Chan J: Immunology of tuberculosis. Annu Rev Immunol. 2001, 19: 93-129. 10.1146/annurev.immunol.19.1.93.CrossRefPubMed
5.
Andersen P, Andersen AB, Sorensen AL, Nagai S: Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J Immunol. 1995, 154 (7): 3359-3372.PubMed
6.
Mustafa AS, Amoudy HA, Wiker HG, Abal AT, Ravn P, Oftung F, Andersen P: Comparison of antigen-specific T-cell responses of tuberculosis patients using complex or single antigens of Mycobacterium tuberculosis. Scand J Immunol. 1998, 48 (5): 535-543. 10.1046/j.1365-3083.1998.00419.x.CrossRefPubMed
7.
Pollock JM, Andersen P: The potential of the ESAT-6 antigen secreted by virulent mycobacteria for specific diagnosis of tuberculosis. J Infect Dis. 1997, 175 (5): 1251-1254.CrossRefPubMed
8.
Masungi C, Temmerman S, Van Vooren JP, Drowart A, Pethe K, Menozzi FD, Locht C, Mascart F: Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis. 2002, 185 (4): 513-520. 10.1086/338833.CrossRefPubMed
9.
Ulrichs T, Munk ME, Mollenkopf H, Behr-Perst S, Colangeli R, Gennaro ML, Kaufmann SH: Differential T cell responses to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors. Eur J Immunol. 1998, 28 (12): 3949-3958. 10.1002/(SICI)1521-4141(199812)28:12<3949::AID-IMMU3949>3.0.CO;2-4.CrossRefPubMed
10.
Berthet FX, Lagranderie M, Gounon P, Laurent-Winter C, Ensergueix D, Chavarot P, Thouron F, Maranghi E, Pelicic V, Portnoi D, Marchal G, Gicquel B: Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science. 1998, 282 (5389): 759-762. 10.1126/science.282.5389.759.CrossRefPubMed
11.
Berthet FX, Rauzier J, Lim EM, Philipp W, Gicquel B, Portnoi D: Characterization of the Mycobacterium tuberculosis erp gene encoding a potential cell surface protein with repetitive structures. Microbiology. 1995, 141 (Pt 9): 2123-2130.CrossRefPubMed
12.
de Mendonca-Lima L, Picardeau M, Raynaud C, Rauzier J, Goguet De La Salmoniere YO, Barker L, Bigi F, Cataldi A, Gicquel B, Reyrat JM: Erp, an extracellular protein family specific to mycobacteria. Microbiology. 2001, 147 (Pt 8): 2315-2320.CrossRefPubMed
13.
Lim EM, Rauzier J, Timm J, Torrea G, Murray A, Gicquel B, Portnoi D: Identification of mycobacterium tuberculosis DNA sequences encoding exported proteins by using phoA gene fusions. J Bacteriol. 1995, 177 (1): 59-65.PubMedPubMedCentral
14.
Timm J, Perilli MG, Duez C, Trias J, Orefici G, Fattorini L, Amicosante G, Oratore A, Joris B, Frere JM, et al: Transcription and expression analysis, using lacZ and phoA gene fusions, of Mycobacterium fortuitum beta-lactamase genes cloned from a natural isolate and a high-level beta-lactamase producer. Mol Microbiol. 1994, 12 (3): 491-504. 10.1111/j.1365-2958.1994.tb01037.x.CrossRefPubMed
15.
Bigi F, Alito A, Fisanotti JC, Romano MI, Cataldi A: Characterization of a novel Mycobacterium bovis secreted antigen containing PGLTS repeats. Infect Immun. 1995, 63 (7): 2581-2586.PubMedPubMedCentral
16.
Cherayil BJ, Young RA: A 28-kDa protein from Mycobacterium leprae is a target of the human antibody response in lepromatous leprosy. J Immunol. 1988, 141 (12): 4370-4375.PubMed
17.
Sorensen AL, Nagai S, Houen G, Andersen P, Andersen AB: Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun. 1995, 63 (5): 1710-1717.PubMedPubMedCentral
18.
Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P: Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun. 1996, 64 (1): 16-22.PubMedPubMedCentral
19.
Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, Small PM: Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 1999, 284 (5419): 1520-1523. 10.1126/science.284.5419.1520.CrossRefPubMed
20.
Skjot RL, Oettinger T, Rosenkrands I, Ravn P, Brock I, Jacobsen S, Andersen P: Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun. 2000, 68 (1): 214-220.CrossRefPubMedPubMedCentral
21.
Arend SM, Geluk A, van Meijgaarden KE, van Dissel JT, Theisen M, Andersen P, Ottenhoff TH: Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infect Immun. 2000, 68 (6): 3314-3321. 10.1128/IAI.68.6.3314-3321.2000.CrossRefPubMedPubMedCentral
22.
Arend SM, Andersen P, van Meijgaarden KE, Skjot RL, Subronto YW, van Dissel JT, Ottenhoff TH: Detection of active tuberculosis infection by T cell responses to early- secreted antigenic target 6-kDa protein and culture filtrate protein 10. J Infect Dis. 2000, 181 (5): 1850-1854. 10.1086/315448.CrossRefPubMed
23.
Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy HA, Mustafa AS, Jensen AK, Holm A, Rosenkrands I, Oftung F, Olobo J, von Reyn F, Andersen P: Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis. 1999, 179 (3): 637-645. 10.1086/314640.CrossRefPubMed
24.
Mustafa AS, Oftung F, Amoudy HA, Madi NM, Abal AT, Shaban F, Rosen Krands I, Andersen P: Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines. Clin Infect Dis. 2000, 30 Suppl 3: S201-5. 10.1086/313862.CrossRefPubMed
25.
Berthet FX, Rasmussen PB, Rosenkrands I, Andersen P, Gicquel B: A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low- molecular-mass culture filtrate protein (CFP-10). Microbiology. 1998, 144 (Pt 11): 3195-3203.CrossRefPubMed
26.
Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS: Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science. 1997, 276 (5317): 1420-1422. 10.1126/science.276.5317.1420.CrossRefPubMed
27.
Ohara N, Ohara-Wada N, Kitaura H, Nishiyama T, Matsumoto S, Yamada T: Analysis of the genes encoding the antigen 85 complex and MPT51 from Mycobacterium avium. Infect Immun. 1997, 65 (9): 3680-3685.PubMedPubMedCentral
28.
Havlir DV, Wallis RS, Boom WH, Daniel TM, Chervenak K, Ellner JJ: Human immune response to Mycobacterium tuberculosis antigens. Infect Immun. 1991, 59 (2): 665-670.PubMedPubMedCentral
29.
Huygen K, Van Vooren JP, Turneer M, Bosmans R, Dierckx P, De Bruyn J: Specific lymphoproliferation, gamma interferon production, and serum immunoglobulin G directed against a purified 32 kDa mycobacterial protein antigen (P32) in patients with active tuberculosis. Scand J Immunol. 1988, 27 (2): 187-194. 10.1111/j.1365-3083.1988.tb02338.x.CrossRefPubMed
30.
Denis O, Tanghe A, Palfliet K, Jurion F, van den Berg TP, Vanonckelen A, Ooms J, Saman E, Ulmer JB, Content J, Huygen K: Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun. 1998, 66 (4): 1527-1533.PubMedPubMedCentral
31.
Tanghe A, D'Souza S, Rosseels V, Denis O, Ottenhoff TH, Dalemans W, Wheeler C, Huygen K: Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun. 2001, 69 (5): 3041-3047. 10.1128/IAI.69.5.3041-3047.2001.CrossRefPubMedPubMedCentral
32.
Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, Gicquel B, Vicaut E, Lagrange PH, Sereni D, Autran B: Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. Aids. 2006, 20 (2): F1-7. 10.1097/01.aids.0000202648.18526.bf.CrossRefPubMed
33.
Andersen P, Munk ME, Pollock JM, Doherty TM: Specific immune-based diagnosis of tuberculosis. Lancet. 2000, 356 (9235): 1099-1104. 10.1016/S0140-6736(00)02742-2.CrossRefPubMed
34.
van Pinxteren LA, Ravn P, Agger EM, Pollock J, Andersen P: Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin Diagn Lab Immunol. 2000, 7 (2): 155-160. 10.1128/CDLI.7.2.155-160.2000.PubMedPubMedCentral
35.
Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P: ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun. 2000, 68 (2): 791-795. 10.1128/IAI.68.2.791-795.2000.CrossRefPubMedPubMedCentral
36.
Cardoso FL, Antas PR, Milagres AS, Geluk A, Franken KL, Oliveira EB, Teixeira HC, Nogueira SA, Sarno EN, Klatser P, Ottenhoff TH, Sampaio EP: T-cell responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 in Brazilian tuberculosis patients. Infect Immun. 2002, 70 (12): 6707-6714. 10.1128/IAI.70.12.6707-6714.2002.CrossRefPubMedPubMedCentral
37.
Doherty TM, Demissie A, Olobo J, Wolday D, Britton S, Eguale T, Ravn P, Andersen P: Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol. 2002, 40 (2): 704-706. 10.1128/JCM.40.2.704-706.2002.CrossRefPubMedPubMedCentral
38.
Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ, Reece WH, Latif M, Pasvol G, Hill AV: Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet. 2001, 357 (9273): 2017-2021. 10.1016/S0140-6736(00)05115-1.CrossRefPubMed
39.
Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, Conlon CP, Pasvol G, Hill AV: Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med. 2001, 163 (4): 824-828.CrossRefPubMed
40.
Bentley-Hibbert SI, Quan X, Newman T, Huygen K, Godfrey HP: Pathophysiology of antigen 85 in patients with active tuberculosis: antigen 85 circulates as complexes with fibronectin and immunoglobulin G. Infect Immun. 1999, 67 (2): 581-588.PubMedPubMedCentral
41.
Wiker HG, Harboe M: The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev. 1992, 56 (4): 648-661.PubMedPubMedCentral
42.
Jo EK, Kim HJ, Lim JH, Min D, Song Y, Song CH, Paik TH, Suhr JW, Park JK: Dysregulated production of interferon-gamma, interleukin-4 and interleukin-6 in early tuberculosis patients in response to antigen 85B of Mycobacterium tuberculosis. Scand J Immunol. 2000, 51 (2): 209-217. 10.1046/j.1365-3083.2000.00663.x.CrossRefPubMed
43.
Schwander SK, Torres M, Carranza CC, Escobedo D, Tary-Lehmann M, Anderson P, Toossi Z, Ellner JJ, Rich EA, Sada E: Pulmonary mononuclear cell responses to antigens of Mycobacterium tuberculosis in healthy household contacts of patients with active tuberculosis and healthy controls from the community. J Immunol. 2000, 165 (3): 1479-1485.CrossRefPubMed
44.
Song CH, Kim HJ, Park JK, Lim JH, Kim UO, Kim JS, Paik TH, Kim KJ, Suhr JW, Jo EK: Depressed interleukin-12 (IL-12), but not IL-18, production in response to a 30- or 32-kilodalton mycobacterial antigen in patients with active pulmonary tuberculosis. Infect Immun. 2000, 68 (8): 4477-4484. 10.1128/IAI.68.8.4477-4484.2000.CrossRefPubMedPubMedCentral
45.
Gascan H, Gauchat JF, Roncarolo MG, Yssel H, Spits H, de Vries JE: Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J Exp Med. 1991, 173 (3): 747-750. 10.1084/jem.173.3.747.CrossRefPubMed
46.
Kitani A, Strober W: Regulation of C gamma subclass germ-line transcripts in human peripheral blood B cells. J Immunol. 1993, 151 (7): 3478-3488.PubMed
47.
Stavnezer J: Immunoglobulin class switching. Curr Opin Immunol. 1996, 8 (2): 199-205. 10.1016/S0952-7915(96)80058-6.CrossRefPubMed
48.
Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, Filgueira MC, Tartar A, Druilhe P: Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood. 1994, 84 (5): 1594-1602.PubMed
49.
Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, Druilhe P: Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun. 2000, 68 (5): 2617-2620. 10.1128/IAI.68.5.2617-2620.2000.CrossRefPubMedPubMedCentral
50.
Rzepczyk CM, Hale K, Woodroffe N, Bobogare A, Csurhes P, Ishii A, Ferrante A: Humoral immune responses of Solomon Islanders to the merozoite surface antigen 2 of Plasmodium falciparum show pronounced skewing towards antibodies of the immunoglobulin G3 subclass. Infect Immun. 1997, 65 (3): 1098-1100.PubMedPubMedCentral
51.
Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P: Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med. 1995, 182 (2): 409-418. 10.1084/jem.182.2.409.CrossRefPubMed
52.
Dhandayuthapani S, Izumi S, Anandan D, Bhatia VN: Specificity of IgG subclass antibodies in different clinical manifestations of leprosy. Clin Exp Immunol. 1992, 88 (2): 253-257.CrossRefPubMedPubMedCentral
53.
Hussain R, Kifayet A, Chiang TJ: Immunoglobulin G1 (IgG1) and IgG3 antibodies are markers of progressive disease in leprosy. Infect Immun. 1995, 63 (2): 410-415.PubMedPubMedCentral
54.
Perlmann P, Perlmann H, Flyg BW, Hagstedt M, Elghazali G, Worku S, Fernandez V, Rutta AS, Troye-Blomberg M: Immunoglobulin E, a pathogenic factor in Plasmodium falciparum malaria. Infect Immun. 1997, 65 (1): 116-121.PubMedPubMedCentral
55.
Briere F, Servet-Delprat C, Bridon JM, Saint-Remy JM, Banchereau J: Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J Exp Med. 1994, 179 (2): 757-762. 10.1084/jem.179.2.757.CrossRefPubMed
56.
Sarthou JL, Angel G, Aribot G, Rogier C, Dieye A, Toure Balde A, Diatta B, Seignot P, Roussilhon C: Prognostic value of anti-Plasmodium falciparum-specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria. Infect Immun. 1997, 65 (8): 3271-3276.PubMedPubMedCentral
Metadata
Title
T-cell and serological responses to Erp, an exported Mycobacterium tuberculosisprotein, in tuberculosis patients and healthy individuals
Authors
Valérie Martinez
Guislaine Carcelain
Edgar Badell
Marc Jouan
Isabelle Mauger
Pierre Sellier
Chantal Truffot
François Bricaire
Sandra M Arend
Tom Ottenhoff
Brigitte Autran
Brigitte Gicquel
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2007
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-7-83

Other articles of this Issue 1/2007

BMC Infectious Diseases 1/2007 Go to the issue

Research article

In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureussevere respiratory infections

Research article

Quantity of ethanol absorption after excessive hand disinfection using three commercially available hand rubs is minimal and below toxic levels for humans

Research article

Serology based disease status of Pakistani population infected with Hepatitis B virus

Research article

U.S. medical resident familiarity with national tuberculosis guidelines

Research article

Superficial and deep sternal wound infection after more than 9000 coronary artery bypass graft (CABG): incidence, risk factors and mortality

Research article

Reduction of Clostridium Difficile and vancomycin-resistant Enterococcus contamination of environmental surfaces after an intervention to improve cleaning methods
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits